Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tamoxifeno oral vs. TamGel vs. control en mujeres con hiperplasia atípica o carcinoma lobulillar in situ

31 de agosto de 2026 actualizado por: Mayo Clinic

Un ensayo aleatorizado de fase IIB de tamoxifeno oral frente a gel tópico de 4-hidroxitamoxifeno frente a control en mujeres con hiperplasia atípica o carcinoma lobulillar in situ

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased risk of breast cancer (BC) (~1-2 % per year). Over two decades ago, placebo-controlled randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by 50% in generally defined high risk women, with ~70% reduction in women at high risk specifically due to atypical hyperplasia.[1] Years later, the side effects and toxicity of oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm compliance.[2, 3] To address the issue of toxicity, two main strategies have been pursued: 1) using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to avoid systemic side effects. The investigators will perform a prospective study of women with AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response. The overall goal of the study is to evaluate short-term changes in background breast tissue induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.

Tipo de estudio

Intervencionista

Inscripción (Actual)

65

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Illinois
      • Evanston, Illinois, Estados Unidos, 60208
        • Northwestern University
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • MD Anderson Cancer center at Cooper

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Willing to return to enrolling institution for follow-up

  • Willing to complete required testing

  • Ability to complete questionnaire by themselves or with assistance

  • Female (sex that was assigned at birth)

  • Ipsilateral intact breast with histology confirmation of atypical ductal or lobular hyperplasia, or lobular carcinoma in situ (LCIS), within the last 12 months, whether surgically excised or not.; OR neither AH nor LCIS but increased breast cancer risk defined as either:

    • Gail model (Breast Cancer Risk Assessment Tool) 5 year breast cancer risk of >= 3%, or
    • International Breast Intervention Study model 10 year breast cancer risk of >= 5%.
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • The effects of topical afimoxifene (4-OHT) gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use at least one effective form of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for 2 months following the last dose of study medications (participant can resume oral birth control pills for effective birth control measures after post-treatment biopsy is done). Effective birth control methods during treatment are: copper and Mirena intrauterine device (IUD), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Tubal Ligation is an acceptable method of birth control. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.

  • Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study.

  • Participants must have acceptable organ and marrow function as judged by treating physician's evaluation of baseline laboratory data.

  • Negative pregnancy (serum or urine) test if of childbearing potential and/or follicle stimulating hormone (FSH) to verify menopausal status.

Exclusion Criteria:

  • Clinically suspicious mass/lesions

  • Breast cancer in the past 5 years.

  • Patients with any history of venous thromboembolic disease, regardless of timeframe (history of varicose veins and superficial phlebitis is allowed).

  • Current pregnancy or lactation.

  • History of other prior breast cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors).

  • Cytotoxic chemotherapy for any indication in last 2 years.

  • Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within the past 5 years unless:

    • Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment, or
    • Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment.
  • Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to pretreatment breast biopsy. Use of vaginally administered estrogens and hormone coated IUD such as Mirena is permitted.

  • History of any prior ipsilateral breast radiotherapy. Previous unilateral radiation of the contralateral side is allowed.

  • Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration).

  • History of endometrial neoplasia

  • Current smoker. Cessation for at least 6 weeks

  • Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine.

  • Participants may not be receiving any other investigational agents within 90 days of enrollment or during this study.

  • History of allergic reactions to tamoxifen.

  • Uncontrolled intercurrent illness that in the judgement of the treating physician would make them unsuitable for study participation

  • Current use of anticoagulation medications.

  • Patients who are breastfeeding.

  • Hemoglobin < 10 g/dL (within 30 days of randomization).

  • Leukocytes < 3,000/microliter (within 30 days of randomization).

  • Platelets < 100,000/microliter (within 30 days of randomization).

  • Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (within 30 days of randomization).

  • Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) > 1.5 x ULN (within 30 days of randomization).

  • Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) > 1.5 x ULN (within 30 days of randomization).

  • Alkaline phosphatase, S > 1.5 x ULN (within 30 days of randomization).

  • Albumin, S > 1.5 x ULN (within 30 days of randomization).

  • Protein, total, S > 1.5 x ULN (within 30 days of randomization).

  • Creatinine > 1.5 x ULN (within 30 days of randomization).

  • Antithrombin III <80% of normal.

  • Fibrinogen >1000 mg/dL.

  • Patients who are taking any medications, herbal products, or over the counter (OTC) products that are moderate or strong CYP2D6 inhibitors or CYP3A inducers. Patients should also refrain from starting any drug or product with these properties during the study. This is to avoid any potential interactions with tamoxifen or 4-OHT.

  • Clinically significant arrhythmia requiring ongoing medication for control / treatment, especially those with high risk of QT prolonging effects.

  • Identification of a clinically suspicious mass on examination.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Oral Tamoxifen 10 mg/day

Oral Tamoxifen 10 mg/day

Ancillary studies

Oral Tamoxifen 10 mg/day

Otros nombres:
  • Tamoxifeno oral
Experimental: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

+oral placebo

Ancillary studies

Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

Otros nombres:
  • Gel tópico
Experimental: Control

Oral and gel placebo

Ancillary studies

placebo pill or placebo gel

Otros nombres:
  • pastilla de placebo
  • gel placebo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Median Lobular Ki67 From Pre-Tamoxifen Breast Biopsy to On-Tamoxifen Biopsy With 4 Weeks of Intervention
Periodo de tiempo: Pre-biopsy to post-biopsy following 4 weeks of intervention

All patients received an oral pill and a topical gel. Prior to assessing non-inferiority of 4-OHT Gel compared to Oral Tamoxifen, treatment effect was assessed within each group by testing for a significant reduction in median lobular Ki67 between PreTam and OnTam biopsy. Median lobular Ki67 is assessed using the percentage of cells stained across all lobules separately at PreTam and OnTam timepoints, evaluated for a difference in median calculated change.

Pre-biopsy to post-biopsy following 4 weeks of intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Amy Degnim, M.D., Mayo Clinic

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de julio de 2021

Finalización primaria (Actual)

15 de octubre de 2024

Finalización del estudio (Actual)

15 de octubre de 2024

Fechas de registro del estudio

Enviado por primera vez

28 de septiembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

29 de septiembre de 2020

Publicado por primera vez (Actual)

30 de septiembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

31 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CA237607
  • 19-011444 (Otro identificador: Mayo Clinic Institutional Review Board)
  • 5R01CA237607-05 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .